FDA Advisors Again Overrule Agency Concerns With Chelsea’s Northera

Drug Industry Daily
A A
Chelsea Therapeutics’ second encounter with an FDA advisory panel over its blood pressure drug Northera has garnered an even stronger positive nod than a 2012 vote that resulted in a surprise complete response letter.

To View This Article:

Login

Subscribe To Drug Industry Daily